Current Report Filing (8-k)
June 12 2020 - 4:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): June 12, 2020 (June 11, 2020)
Y-MABS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
001-38650
|
|
47-4619612
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
230 Park Avenue
Suite 3350
New York, New
York 10169
(Address of principal
executive offices) (Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol
|
|
Name of each exchange on which registered:
|
Common Stock, $0.0001 par value
|
|
YMAB
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 11, 2020, Y-mAbs Therapeutics, Inc.,
(the “Company”) held its annual meeting of stockholders (the “Annual Meeting”).
The following proposals were submitted
to the stockholders at the Annual Meeting:
|
1.
|
the election of three (3) Class II directors, James I. Healy, M.D., Ashutosh Tyagi, M.D.,
and Laura J. Hamill, nominated by the Company’s Board of Directors, each to serve for a three-year term to expire at the 2023 annual meeting
of stockholders, each such nominee to hold office until his/her successor has been duly elected and qualified or until his/her
earlier death, resignation or removal; and
|
|
2.
|
the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent
registered public accounting firm for the Company’s fiscal year ending December 31, 2020.
|
The proposals are described in detail in
the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 28, 2020. No other proposals
were submitted to the stockholders at the Annual Meeting.
The number of shares of common stock entitled
to vote at the Annual Meeting was 39,757,623.
All matters submitted to a vote of the
Company’s stockholders at the Annual Meeting were approved and all director nominees were elected. The number of votes cast
for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:
1. Election of three Class II directors.
Nominee
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
James I. Healy, M.D.
|
|
21,179,389
|
|
|
6,623,361
|
|
|
3,414,604
|
|
Ashutosh Tyagi, M.D.
|
|
24,803,197
|
|
|
2,999,553
|
|
|
3,414,604
|
|
Laura J. Hamill
|
|
27,759,750
|
|
|
43,000
|
|
|
3,414,604
|
|
The Company’s stockholders elected
James I. Healy, M.D., Ashutosh Tyagi, M.D., and Laura J. Hamill each to serve for a three-year term to expire at the 2023 annual
meeting of stockholders, each such nominee to hold office until his/her successor has been duly elected and qualified or until
his/her earlier death, resignation or removal.
2. Ratification of appointment of independent
registered public accounting firm.
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Votes
|
|
31,217,080
|
|
|
104
|
|
|
170
|
|
|
0
|
|
The Company’s stockholders ratified
the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2020.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
Y-MABS THERAPEUTICS, INC.
|
|
|
|
|
Date: June 12, 2020
|
|
By:
|
/s/ Thomas Gad
|
|
|
|
Thomas Gad
|
|
|
|
Founder, Chairman, President and Head of Business Development & Strategy
|
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Apr 2023 to Apr 2024